Purple Biotech Ltd.
PPBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 34.35 | -0.18 | 0.10 |
| FCF Yield | -118.47% | -105.05% | -66.51% | -21.93% |
| EV / EBITDA | -0.70 | -0.24 | -0.51 | -3.37 |
| Quality | ||||
| ROIC | -32.93% | -59.70% | -47.33% | -27.11% |
| Gross Margin | 0.00% | -0.10% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.97 | 1.00 | 0.77 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 27.91% | -17.48% | -11.70% | -23.99% |
| Safety | ||||
| Net Debt / EBITDA | 1.02 | 0.71 | 0.68 | 0.58 |
| Interest Coverage | -24.62 | -10.21 | -337.36 | -84.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,855.24 | -6,577.45 | -6,484,833.33 | -9,775,363.64 |